ResMed Inc. (rmd)

RMD — Company Overview

ResMed Inc. (RMD) trades on NYQ as part of the Healthcare peer group (Medical Instruments & Supplies).

RMD — Business Description

RMD represents a Medical Instruments & Supplies business in the Healthcare segment. ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system tha…

Official website: https://www.resmed.com.

RMD — Investment Thesis

At a high level, RMD offers exposure to Healthcare with metrics outlined below from public market data.

• Revenue is expanding at roughly 8.6% year-over-year (public data).
• Trailing P/E of 21.27× sits in a moderate band relative to high-growth peers.
• Forward P/E (16.80×) is below trailing P/E — earnings may be expected to improve.
• Dividend yield near 1.2% adds an income component to total return.
• Equity market capitalization is approximately $32.07B.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

RMD — Financial Health

Key financial health indicators for ResMed Inc. are derived exclusively from public data — no proprietary estimates.

Profit margin of 26.9% indicates solid bottom-line conversion. Positive free cash flow of $939.25M supports balance-sheet flexibility.

RMD — Growth Outlook

Growth outlook for ResMed Inc. (RMD) depends on demand trends in Medical Instruments & Supplies and the company's ability to convert revenue into sustainable earnings.

• Revenue growth of 8.6% suggests steady but measured expansion.
• Earnings growth of 2.4% year-over-year supports improving profitability.
• Price is 22.0% below the 52-week high.
• Shares trade 23.3% above the 52-week low — limited rebound so far.

RMD — Competitive Position

ResMed Inc. (RMD) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

• Competes within Healthcare, specifically in Medical Instruments & Supplies.
• Market capitalization of $32.07B places RMD among large-cap peers.
• Gross margin near 61.6% may reflect pricing power or favorable mix.

RMD — Summary

ResMed Inc. (RMD) is a large-cap Healthcare company focused on Medical Instruments & Supplies, listed on NYQ. Last price $222.30 with market cap $32.07B. Trailing P/E 21.27×. Revenue grew 8.6% year-over-year per public data. Notable strengths include revenue growth of 8.6% year-over-year. Premium Terminal tools for ResMed Inc. add ownership analytics, news, and richer estimate history beyond this public summary.